President and Chief Executive Officer, Blade Therapeutics
| Role | Organisation | Sources |
|---|---|---|
| President and Chief Executive Officer | Blade Therapeutics | OneVentures portfolio (Wed 12 Aug 2020), OneVentures portfolio (Mon 10 Aug 2020) |
Stories naming Wendye Robbins. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Blade Therapeutics reports its Phase 2 trial of BLD-2660 in COVID-19 pneumonia has enrolled half its 120-patient goal, with full enrollment expected in the third quarter of 2020.
Blade Therapeutics appoints Mark Timney as board chairman, succeeding co-founder Luke Evnin; the release recalls its roughly $90 million raised from investors including OneVentures and The Medicines Company's $9.7 billion sale to Novartis.